Patients were on a stable PAH therapy with a phosphodiesterase type 5 inhibitor or soluble guanylate cyclase stimulator, endothelin receptor antagonist, or prostanoid/prostacyclin receptor agonist (oral/inhaled) for ≥3 months prior to first FCM administration (≙ baseline). This evidence concerns the gene PTGIR and pulmonary arterial hypertension.